USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER
The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
1 .- 31 . (canceled)
32 . A method of treating a cancer of the liver, comprising administering an effective amount of a TLR5 agonist to a subject in need thereof, wherein:
cancer does not express Toll-Like Receptor 5 (TLR5) and
the TLR5 agonist is flagellin or a flagellin derivative.
33 . The method of claim 32 , wherein the cancer is metastatic.
34 . The method of claim 33 , wherein the metastatic cancer is selected from melanoma, colon, breast, prostate, or a hematological malignancy.
35 . The method of claim 34 , wherein the hematological malignancy is lymphoma.
36 . The method of claim 32 , wherein the cancer is a tumor.
37 . The method of claim 32 , wherein the TLR5 agonist is administered as a monotherapy.
38 . The method of claim 32 , wherein the subject is not receiving a combination cancer therapy.
39 . The method of claim 32 , wherein the subject is not receiving radiation therapy.
40 . The method of claim 32 , wherein the subject has sufficient innate immunity.
41 . The method of claim 40 , wherein the sufficient innate immunity level is equivalent to the level required for eligibility for a first or subsequent round of chemotherapy.
42 . The method of claim 32 , wherein the subject has a white blood cell count that is within the clinically normal range.
43 . The method of claim 32 , wherein the TLR5 agonist is administered to the subject before, after, or concurrent with removal of a tumor.
44 . The method of claim 32 , wherein the TLR5 agonist is co-administered with a FAS agonist.
45 . The method of claim 44 , wherein the FAS agonist is a FAS agonist antibody.
46 . The method of claim 32 , wherein the TLR5 agonist comprises the amino acid sequence of SEQ ID NO: 8.
47 . The method of claim 33 , wherein the TLR5 agonist comprises the amino acid sequence of SEQ ID NO: 8.
48 . The method of claim 32 , wherein the treating comprises reducing a recurrence of the cancer.
49 . The method of claim 48 , wherein the cancer recurrence is selected from a metastasis or a tumor regrowth.
50 . The method of claim 49 , wherein the TLR5 agonist comprises the amino acid sequence of SEQ ID NO: 8.